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Abstract
BACKGROUND: Neuromyelitis optica (NMO) (also known as opticomyelitis, Devic’s syndrome/disease) is an 
idiopathic inflammatory disorder of the central nervous system characterized by predominant involvement of the optic 
nerves, spinal cord, and extensive transverse myelitis. To date, there are no convincing clinical trials that would fully 
evaluate the efficacy and safety of drugs for the treatment and prevention of NMO exacerbation. Taking into account 
the malignant course that quickly leads to disability of young, economically active population, the issues of searching 
for effective methods of NMO treatment remain highly urgent.
AIM: The purpose of the study was to examine available modern methods of treatment and prevention of NMO 
exacerbation, which have potential and require further detailed clinical trials to ensure possible application of these 
treatment options in clinical practice.
MATERIALS AND METHODS: We have reviewed previously applied and modern methods of treatment. We 
have analyzed systematic reviews, clinical, randomized, and retrospective studies of scientific medical databases: 
PubMed, Cochrane, The Lancet, UpToDate, and reviews of world medical journals in Russian and English.
CONCLUSIONS: The authors concluded that there is a sufficient number of drugs and combinations of methods 
of Devic’s disease treatment. We were interested in combinations of rituximab (RIT) and autologous stem cell 
transplantation, RIT and fetal hepatocyte transplantation, and RIT and strengthening the effect by plasmapheresis 
sessions. However, successful implementation of these methods in clinical practice requires conducting controlled 
clinical trials with a larger number of patients and longer follow-up periods.
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Introduction
Neuromyelitis optica (NMO) (opticomyelitis, 
Devic’s syndrome/disease) is an idiopathic inflammatory 
disease of the central nervous system (CNS) 
characterized by predominant involvement of the optic 
nerves, spinal cord, and extensive transverse myelitis 
longitudinally extensive transverse myelitis at the level 
of the thoracic, less frequently cervical segments with 
relative preservation of the brain [1], [2].
Devic’s disease is more common among 
people of African and Asian descent. In countries of 
the Asia-Pacific Region, its prevalence is 7.6–17.3% 
of all demyelinating CNS disorders. In European 
countries, NMO accounts for <1–2%. The epidemiology 
of opticomyelitis should take into account the fact 
that some cases are often misinterpreted as multiple 
sclerosis, recurrent transverse myelitis, and retrobulbar 
neuritis. NMO is 9 times more common in women than 
in men [3]. Typically, the disease develops in individuals 
aged 35–47 years. In most cases, it is malignant, leads 
to severe disability and death. It is therefore necessary 
to determine the correct diagnosis and prescribe 
adequate therapy as soon as possible.
There are the following diagnostic criteria for 
Devic’s disease (according to D.H. Miller 2008): 
Large criteria (all criteria are required):
•	 Optical neuritis
•	 Transverse myelitis with spinal cord lesions 
occupying more than three segments of the 
spine (radiologically proven focal area)
•	 Elimination of systemic diseases with a similar 
clinical pattern (systemic lupus erythematosus, 
sarcoidosis, vasculitis, and Sjogren’s 
syndrome).
Small criteria (at least one criterion is required):
•	 Changes in T2 regime that is not in the Barcoff’s 
criteria list (included in McDonald’s criteria)
•	 Presence of foci in the medulla oblongata 
(dorsal sections) that merge or do not merge 
with spinal cord foci
•	 Presence of foci in the trunk and/or 
hypothalamus
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•	 Presence of “linear” foci localized in the 
periventricular zone or callous body region, 
having “Dawson’s fingers” shape, without 
spreading into the parenchyma
•	 Identification of antibodies to aquaporin in 
blood serum or cerebrospinal fluid [4].
Relevance
To date, there are no convincing clinical 
trials that would fully evaluate the efficacy and safety 
of drugs for the treatment and prevention of NMO 
exacerbation. Taking into account the malignant course 
that quickly leads to disability of young, economically 
active population, the issues of searching for effective 
methods of NMO treatment remain highly urgent.
Goals and Objectives
The purpose of this review is to examine 
available modern methods of treatment and prevention 
of NMO exacerbation that has potential and require 
further extensive clinical trials.
The objective is to assess the possibility of 
applying these methods of treatment in clinical practice: 
To improve prognosis, reduce disability, and death rates.
We have reviewed previously applied and 
modern methods of treatment. According to the 2015 
clinical protocol used in the Republic of Kazakhstan, the 
multiple sclerosis disease-modifying drugs (MSDMD 
therapy) were earlier applied in NMO treatment. The 
following drugs were used as the main ones: Interferons 
β (interferon – β-1a subcutaneously 3 times a week, 
interferon – β-1b 9.6 mln IU subcutaneously alternate 
day, and interferon – 1a 30 mcg intramuscularly once a 
week), glatiramer acetate, and natalizumab [5].
There are conflicting data on both the 
effectiveness of preventive immunomodulatory 
therapy (interferons beta, glatiramer acetate) and the 
negative effect of increased relapses. In this regard, 
immunosuppressive rather than immunomodulatory 
therapy is recommended for NMO long-term treatment [6].
To date, many countries, as well as the 
Republic of Kazakhstan, apply plasmapheresis (PP) 
courses, hormonal pulse therapy, and prednisolone 
supporting therapy for therapeutic purposes.
In the case of severe, rapidly progressive 
disease, low-efficiency glucocorticosteroid therapy, 
extracorporeal detoxication, patients with NMO are 
prescribed courses of immunosuppressive therapy: 
Cyclophosphamide, mitoxantrone, and azathioprine 
(AZA). Stem cell therapy helps to improve the quality 
of life, as well as supports patients in many countries.
Seven tertiary medical centers in the United 
States and England conducted a retrospective multi-
center study with 25 patients from 7 centers to evaluate 
the use of RIT targeted therapy in adults with NMO. 
Before RIT therapy, the study participants received 
various immunosuppressive drugs: Mitoxantrone, 
prednisolone, AZA, beta-interferons, and the effect of 
which was not observed.
Results
With an average 19-month follow-up period, the 
median annual relapse rate after treatment was lower 
than before treatment (0 [range 0–3.2] vs. 1.7 [range 
0.5–5] of relapses, p < 0.001). Disability has improved 
or stabilized in 20 of 25 patients (80%, p = 0.02). Two 
patients died during the follow-up period, 1 due to brain 
stem relapse, and 1 due to suspected septicemia. 
Infections were recorded in 20% of patients.
The use of RIT resulted in clinical and 
radiological remission in 80% of patients. However, 
despite the visible efficacy, this drug has a high risk 
of relapse after the successful time course of the 
drug, 6–12 months later. Furthermore, with chronic 
administration of RIT, the risk of infectious complications 
and oncological diseases is high, that is why the question 
about this method of therapy remains open [7]. The 
authors considered one of the options for prolongation 
and maintenance of remission after administration of 
RIT – autologous transplantation of hematopoietic stem 
cells and long-term administration of mycophenolate 
mofetil. As an example, there were two clinical cases 
amount patients from their center. In the first case, after 
the RIT course, the tactic of long-term administration of 
mycophenolate mofetil was chosen for further disease 
management. The patient continued to have remission 
of the underlying disease in the course of this therapy. In 
the second case, allo-HSCT was conducted. Moreover, 
an assessment of the neurological status was conducted 
on day 2000 after the transplantation, which showed 
positive dynamics in the form of motor activity recovery 
(walking without support). However, these cases are 
not indicative due to the small number of patients and a 
short follow-up period [8].
In the retrospective study (Plasauto EZ, Asahi 
Kasei Medical, Tokyo, Japan), PP was conducted in 15 
patients with NMO exacerbation. The immediate effect 
after 6 months, change of serum levels of anti-AQP4 
antibodies was observed in the course of treatment, 
which led to significant improvement of neurological 
disability in patients with NMO [9].
Monoclonal antibodies are one of the fastest-
growing areas of specific therapy for autoimmune and 
demyelinating diseases. The main targets of monoclonal 
antibodies in autoimmune and demyelinating diseases 
are T- and B-lymphocytes, cytokines, complement, and 
adhesion molecules. The UBC Hospital in Vancouver, 
British Columbia, Canada, conducted a multi-center, 
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double-blind, randomized, and placebo-controlled 
study with 230 participants. The participants were 
randomized (3:1) within the period from January 6, 
2015 to September 24, 2018, with 174 participants 
randomized to inebilizumab and 56 participants – 
to placebo. Only 21 (12%) of 174 participants who 
received inebilizumab had a relapse, compared to 22 
(39%) of 56 participants who received a placebo. Thus, 
inebilizumab clearly has shown efficacy in reducing the 
risk of relapse of opticomyelitis [10].
There is strong evidence of the role of 
the complement system in the NMO pathogenesis 
and, therefore, the benefits of targeted therapy. The 
inflammatory process in opticomyelitis involves an obvious 
vasculocentric deposition of activated complement.
Selective inhibition of early stages in the 
classical complement pathway has a potential 
advantage over inhibition of later stages. Interest was 
expressed in the therapeutic potential of C1-inhibitor 
(C1-inh). In this study, experiments were performed 
on rats. The investigators were representatives of the 
Department of Medicine and Physiology, the University 
of California in San Francisco. Lewis rats were 
purchased at the Charles River Laboratory (Wilmington, 
Massachusetts). To investigate the activity of C1-inh 
complement in rats, C1-inh was injected intravenously 
at a dose of 600 units/kg, and the serum obtained at 
different times was analyzed for complement activity. 
The study used an artificial model of opticomyelitis in 
rats, the pathology of which was caused by IgG injection 
which led to characteristic pathological features, 
including damage to astrocytes, inflammation, and 
demyelination after 5 days. Pathological changes in 
this model were completely prevented by inhibiting the 
complement system with cobra venom toxin, indicating 
that the complement activity in rats is necessary for 
further pathological changes. It should be noted that 
despite the same activity of complement in rats and 
humans, studies conducted using experimental models 
of rats should be extrapolated to humans with extreme 
caution. The final evaluation of the potential efficacy of 
C1-inh will require controlled clinical trials [11].
Clinical trials on the efficacy of using fetal 
hepatocytes in MS treatment were conducted in 
Kazakhstan. After fetal neurotransplantation in 93.3% 
of subjects during 36 months, positive dynamics in the 
form of a 21.9% regression of clinical symptomatology 
on the eating disorder diagnostic scale was observed. 
Magnetic resonance imaging (MRI) showed positive 
dynamics manifested by the reduction of number and 
size of lesions with regression of surrounding perifocal 
edema. The application of this treatment method is 
effective for NMO and will help to maintain remission 
after administration of RIT [12].
At Shandong Provincial Hospital, in the period from 
December 1, 2012, to May 31, 2016, patients with NMO 
received AZA, mycophenolate mofetil (MMF), or low doses 
of RIT (RTX) for 6 months. The annual relapse rate, EDSS 
scores, CD19 + B-cells in peripheral blood, serum AQP-
4-IgG titer, and adverse drug reactions were compared 
between the three groups. In the AZA group (n = 22), the 
MMF group (n = 30) and the RTX group (n = 20), 54.5%, 
60.0%, and 65.0% of patients achieved a relapse-free 
state, while the EDSS score improved in 90.9%, 83.3%, 
and 90.0% of patients, respectively. Decreased RTX dose 
had a significant effect on the reduction of CD19 + B-cell 
count (p < 0.01). Compared to the AZA group, the MMF 
group and the RTX group obviously reduced AQP-4-IgG 
titer and have fewer side effects. Efficacy was found in the 
course AZA, MMF administration, and reduction of RIT 
dose. Low RTX doses were more effective than others 
in reducing CD19 B-cell count. MMF and low RTX doses 
reduced AQP-4-IgG titer and led to fewer side effects than 
AZA. However, a multi-center study is still needed to find a 
more effective therapeutic regimen [13].
An open randomized clinical study was 
conducted in the Neurology Department of Kashani 
Hospital, a part of the Isfahan University of Medical 
Sciences, Isfahan, Iran, in the period from 09.2015 to 
12.2016. The first group received AZA; the second group 
received RIT. There was a significant decrease in relapses 
and EDSS scores among patients with opticomyelitis in 
response to AZA and RIT, although a more favorable 
response was observed in RIT patients. The number of 
side effects did not differ significantly between the two 
groups. In this study, more relapse-free patients were 
found in the RIT group than in the AZA group (78.8% vs. 
54.3%). In addition, both ARR (1.09 vs. 0.49) and EDSS 
(0.98 vs. 0.44) were observed to be lower in RIT patients 
than in AZA patients. Based on these results, RIT is 
an excellent drug for preventing relapse and reducing 
disability in patients with opticomyelitis [14].
A double-blind, placebo-controlled, randomized 
2 phase study (RENEW) was conducted in 33 clinical 
bases in Europe, Canada, and Australia. The study 
involved 82 patients aged 18–35 years with a newly 
diagnosed NMO. After hormonal pulse therapy with 
methylprednisolone, patients were randomized to two 
groups: Opicinumab or placebo. The follow-up period 
was 32 weeks. The therapy efficacy was assessed by 
a recovery of evoked visual potentials, improvement of 
functions of the damaged optic nerve, clinical positive 
manifestations. No statistically significant differences in 
changes in brain MRI were found between the groups.
Opicinumab did not lead to remyelination 
processes, compared to placebo. However, 
remyelination is still considered possible and requires 
further clinical trials [15].
A randomized, placebo-controlled, and double-
blind study of patients with NMO was conducted in the 
National Institute of Neuroscience, National Center of 
Neurology and Psychiatry, Ogawa-Higashi, Kodaira, 
Tokyo, Japan. The groups of patients were randomized 
in a 1:1 ratio, as seropositive or seronegative to AQP4-
IgG. Subjects received satralizumab in 120 mg dose or 
placebo. A relapse occurred in 8 patients (20%) who 
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received satralizumab and in 18 (43%) who received 
placebo (risk ratio 0.38; confidence interval 95% [CI], 
0.16–0.88). The frequency of serious side effects and 
infections did not differ between these groups. The 
authors concluded that satralizumab, which was added 
to immunosuppressant in patients with NMO, resulted 
in a lower risk of relapse than placebo but were no 
different from placebo in its effect on pain or fatigue [16].
The efficacy of the subcutaneous administration 
of tocilizumab (TCZ) for NMO is unknown. In two tertiary 
US centers, a retrospective analysis of data from 
patients with NMO who received TCZ for more than 6 
months between 2014 and 2019 was conducted. During 
treatment with TCZ, eight patients (66.6%) had no 
relapses, one patient (8.3%) had 1 relapse, two patients 
(16.6%) had 2 relapses, and one patient (8.3%) had 3 
relapses. One patient who received TCZ died after severe 
myelitis. The administration of TCZ for NMO reduced the 
relapse rate in two small series of cases. However, the 
clinical protocol, which requires frequent intravenous 
injections, may have a negative impact on treatment 
adherence, especially in patients with disabilities, thereby 
reducing efficacy. Subcutaneous treatment with TCZ 
for opticomyelitis is similar to the effect of intravenous 
administration. Subcutaneous administration of TCZ also 
has the advantage that it is more cost-effective compared 
to the newer anti-IL-6 agents. The low risk of serious 
complications and the high efficacy of TCZ raise the 
question of whether it can be used as first-line therapy for 
opticomyelitis, especially in patients with active disease. 
Comparative prospective studies on the administration of 
this drug are justified [17].
The Johns Hopkins University, Baltimore 
studied PP efficacy for NMO: The first group of 192 
patients; the second group of 38 patients used the 
immunoabsorption (IA) method. Both types of PP were 
found to be equally effective. This suggests that the 
removal of IgG antibodies is an important treatment 
effect of PP for NMO. It is also an important factor 
that the use of (PP or IA) as first-line therapy and the 
initiation of PP within 3 days of relapse provide good 
clinical results. About 40% of patients who received PP 
within 3 days after relapse initiation have returned to 
their baseline, compared to <4% of those who initiated 
PP within 7 days. Thus, early PP is the preferred 
treatment for acute NMO relapses [18].
The Saitama Medical Center, Kamoda, 
Kawagoe, Japan conducted a study involving 50 
patients: 42 of patients had a positive result to anti-
AQP4 antibodies and 8 – a negative result. It showed 
the efficacy of co-administration of tacrolimus and 
prednisolone, which clearly inhibited the relapse rate of 
both anti-AQP4-positive and negative NMO [19].
A multi-center, double-blind, randomized, and 
placebo-controlled study was conducted in hospitals 
and specialized clinics in 25 countries in the period from 
06.01.2015 to 24.09.2018. Participants in the study 
were adult patients aged over 18 years, diagnosed 
with NMO, with 8 or fewer scores on the EDSS scale. 
Two hundred thirty participants were randomized to two 
groups: 174 participants received inebilizumab and 56 
received placebo. Twenty-one (12%) of 174 participants 
who received inebilizumab had an acute episode; 22 
(39%) of 56 participants in the placebo group had a 
relapse. Serious adverse events occurred in eight (5%) 
of 174 participants who received inebilizumab and in 
five (9%) of 56 participants who received a placebo.
Compared to placebo, inebilizumab reduces 
the risk of NMO relapse. However, inebilizumab has 
potential as an evidence-based treatment of patients 
with NMO [20].
An international randomized, placebo-
controlled, and double-blind clinical study prevent 
was conducted in 143 patients with AQP4-IgG+ NMO. 
After 48 weeks of therapy, 98% of patients receiving 
eculizumab noted no relapse of the disease; in the 
placebo group – 63%. The duration of the relapse-free 
period in the eculizumab group was 144 weeks. Changes 
in the EDSS scale were not statistically significant in 
comparison with the control group: −0.18 versus +0.12.
As for prevention, eculizumab significantly 
reduced the assessed risk of relapse compared to 
placebo. The study was discontinued after 23 of 24 
predetermined assessed relapses; these relapses 
occurred in 3 (3%) of 96 patients in the eculizumab group 
and in 20 (43%) of 47 patients in the placebo group (risk 
ratio [HR] 0.06; 95% CI 0.02–0.20; p < 0.001).
According to the study, the disability rate of 
those receiving eculizumab is lower than that of those 
receiving placebo because there was an increase in 
EDSS score (11.5 vs. 23.4%; p < 0.05) or HAI score 
(8.3 vs. 23.4%; p < 0.01) between the baseline and the 
end of the study.  Based on a categorical analysis of 
clinically significant changes in SF-36 score, eculizumab 
significantly (p < 0.05) reduces the likelihood of physical 
component score (PCS) worsening and increases the 
likelihood of PCS improvement compared to placebo. 
Thus, eculizumab significantly reduced the risk of 
relapse compared to placebo in patients with AQP4-
IgG+ NMO, about a quarter of whom did not receive 
immunosuppressive therapy. All patients showed 
positive dynamics in the form of improved neurological 
symptoms and improved quality of life. Eculizumab 
provides an effective, well-tolerated, and approved 
NMO treatment option [21].
Conclusions
We have concluded that there are a sufficient 
number of drugs and combinations of treatments for 
Devic’s disease. We were interested in combinations 
of RIT and autologous stem cell transplantation, RIT 
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and fetal hepatocyte transplantation, and RIT and 
strengthening the effect by PP sessions. However, 
successful implementation of these methods in clinical 
practice requires conducting controlled clinical trials with 
a larger number of patients and longer follow-up periods. 
The follow-up requires a comprehensive assessment 
of the efficacy of treatment, the development of side 
effects in the administration of these combinations. We 
hope that many ongoing clinical trials will be justified and 
that the prognosis of Devic’s disease will be favorable 
in the future.
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